Transcranial Magnetic Stimulation in Bipolar Depression
NCT ID: NCT00186758
Last Updated: 2011-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2002-07-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
to determine if non-responders can become responders if treated on the other side of the hemisphere
(rTMS)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression
NCT01566591
Transcranial Magnetic Treatment (TMS) in Unipolar Depression
NCT00186784
Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression
NCT01583023
Efficacy of rTMS in Bipolar Depression
NCT02749006
Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression
NCT01586793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1, Phase l, True or Sham
this treatment will be True or Sham (placebo) on one side of the head, phase I
Transcranial Magnetic Stimulation (TMS)
Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.
Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
2, phase ll, Sham or True
This treatment will be Sham(placebo)or True on the other side of the head phase II.
Transcranial Magnetic Stimulation (TMS)
Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.
Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Magnetic Stimulation (TMS)
Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.
Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no physical health problems
Exclusion Criteria
* History of Epilepsy
* Pregnancy
* Pacemaker
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University, Kingston, Ontario
OTHER
St. Joseph's Healthcare Hamilton
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
McMaster University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Hasey, MD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Joseph's Healthcare, rTMS Laboratory, Mood Disorder Program, 100 West Fifth Street
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMS2092
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.